Imiloxan hydrochloride

Pricing Availability   Qty
说明: Highly selective α2B antagonist
别名: RS 21361
化学名: 2-(1-Ethyl-2-indazoyl)methyl-1,4-benzodioxan hydrochloride
纯度: ≥98% (HPLC)
说明书
引用文献
评论
文献 (2)

生物活性 for Imiloxan hydrochloride

Imiloxan hydrochloride is a moderately potent, but highly selective α2-adrenoceptor antagonist, the only reported selective antagonist at the α2B-adrenoceptor not having potent α1-adrenoceptor antagonist activity.

许可信息

Sold with the permission of Roche Bioscience

技术数据 for Imiloxan hydrochloride

分子量 280.75
公式 C14H16N2O2.HCl
储存 Desiccate at RT
纯度 ≥98% (HPLC)
CAS Number 81167-22-8
PubChem ID 172975
InChI Key ANDJPJNFVJXEKX-UHFFFAOYSA-N
Smiles Cl.CCN1C=CN=C1CC1COC2=CC=CC=C2O1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Imiloxan hydrochloride

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
water 28.07 100

制备储备液 for Imiloxan hydrochloride

以下数据基于产品分子量 280.75。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 3.56 mL 17.81 mL 35.62 mL
5 mM 0.71 mL 3.56 mL 7.12 mL
10 mM 0.36 mL 1.78 mL 3.56 mL
50 mM 0.07 mL 0.36 mL 0.71 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for Imiloxan hydrochloride

分析证书/产品说明书
选择另一批次:

参考文献 for Imiloxan hydrochloride

参考文献是支持产品生物活性的出版物。

Michel et al (1990) Assessment of imiloxan as a selective α2B-adrenoceptor antagonist. Br.J.Pharmacol. 99 560 PMID: 1970500

Michel and Whiting (1981) 2-(2-Imidazolylmethyl)-1,4-benzodioxans, a series of selective alpha2-adrenoceptor antagonists. Br.J.Pharmacol. 74 255P


If you know of a relevant reference for Imiloxan hydrochloride, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Adrenergic α2 Receptor Antagonists

关键词: Imiloxan hydrochloride, Imiloxan hydrochloride supplier, selective, α2B-adrenoceptor, alpha2B-adrenoceptor, antagonists, α2b-adrenergic, alpha2b-adrenergic, a2-adrenoceptor, a2-adrenergic, Receptors, RS21361, RS, 21361, Adrenergic, Alpha-2, 0986, Tocris Bioscience

篇 Imiloxan hydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 Imiloxan hydrochloride 的引用文献。 您是否知道使用了 Tocris Imiloxan hydrochloride 的优秀论文? 请告知我们.

Imiloxan hydrochloride 的评论

目前没有该产品的评论。 Be the first to review Imiloxan hydrochloride and earn rewards!

Have you used Imiloxan hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.